

Lipases in the preparation of beta-blockers

Citation for published version (APA):

Kloosterman, M., Elferink, V. H. M., Iersel, van, J., Roskam, J. H., Meijer, E. M., Hulshof, L. A., & Sheldon, R. A. (1988). Lipases in the preparation of beta-blockers. Trends in Biotechnology, 6(10), 251-256. https://doi.org/10.1016/0167-7799(88)90057-1

DOI: 10.1016/0167-7799(88)90057-1

Document status and date:

Published: 01/01/1988

Document Version:

Publisher's PDF, also known as Version of Record (includes final page, issue and volume numbers)

Please check the document version of this publication:

• A submitted manuscript is the version of the article upon submission and before peer-review. There can be important differences between the submitted version and the official published version of record. People interested in the research are advised to contact the author for the final version of the publication, or visit the DOI to the publisher's website.

• The final author version and the galley proof are versions of the publication after peer review.

• The final published version features the final layout of the paper including the volume, issue and page numbers.

Link to publication

General rights

Copyright and moral rights for the publications made accessible in the public portal are retained by the authors and/or other copyright owners and it is a condition of accessing publications that users recognise and abide by the legal requirements associated with these rights.

- · Users may download and print one copy of any publication from the public portal for the purpose of private study or research.
- You may not further distribute the material or use it for any profit-making activity or commercial gain
 You may freely distribute the URL identifying the publication in the public portal.

If the publication is distributed under the terms of Article 25fa of the Dutch Copyright Act, indicated by the "Taverne" license above, please follow below link for the End User Agreement:

www.tue.nl/taverne

Take down policy

If you believe that this document breaches copyright please contact us at:

openaccess@tue.nl

providing details and we will investigate your claim.

- 13 Thorpe, P. E., Ross, W. C., Brown, A. N. et al. (1986) Eur. J. Biochem. 140, 63–71
- 14 Greenfield, L., Johnson, V. G. and Youle, R. J. (1987) *Science* 238, 536– 539
- 15 Chang, M-S., Russell, D. W., Uhr, J. W. and Vitetta, E. S. (1987) *Proc. Natl Acad. Sci. USA* 84, 5640–5644
- 16 Richer, G., Carriere, D., Blythman, H. E. and Vidal, H. (1982) in Lectins – Biology, Biochemistry, Clinical Biochemistry (Vol. 2) Walter de Gruyter
- 17 Robertus, J. D., Piatek, M., Ferris, R. and Houston, L. L. (1987) *J. Biol. Chem.* 262, 19–20
- 18 Vitetta, E. S. and Thorpe, P. E. (1985) Cancer Drug Delivery 3, 191–197
- 19 Abuchowski, A., McCoy, J. R., Palczuk, N. C., van Es, T. and Davis, F. F. (1977) *J. Biol. Chem.* 252, 3582– 3586
- 20 Köhler, G. and Milstein, C. (1975) Nature 256, 495–497
- 21 Ghose, T. and Blair, A. H. (1986) CRC Crit. Rev. Ther. Drug Carrier Syst. 3, 263–359

- 22 Laurent, G., Kuhlein, E., Casellas, P. et al. (1986) Cancer Res. 46, 2289–2294
- 23 Sears, H. F., Atkinson, B., Mattis, J. et al. (1982) Lancet i, 762–765
- 24 Till, M., May, R. D., Uhr, J. W., Thorpe, P. E. and Vitetta, E. S. (1988) *Cancer Res.* 48, 1119–1123
- 25 Fodstad, O., Kvalheim, G., Pihl, A., Godal, A. and Funderud, S. (1988) J. Natl Cancer Inst. 80, 439–443
- 26 Casellas, P., Bourrie, B. J., Gros, P. and Jansen, F. K. (1984) J. Biol. Chem. 259, 9359–9364
- 27 Thorpe, P. E. and Ross, W. C. J. (1982) Immunol. Rev. 62, 119–158
- 28 Carlsson, J., Drevin, H. and Axen, R. (1978) *Biochem. J.* 173, 723–737
- 29 King, T. P. and Kochoumian, L. (1978) Biochemistry, 17, 1499–1506
- 30 Thorpe, P. É., Blakey, D. C., Brown, A. N. F. et al. (1987) J. Natl Cancer Inst. 79, 1101–1112
- 31 Blakey, D. C., Watson, G. J., Knowles, P. P. and Thorpe, P. E. (1987) *Cancer Res.* 47, 947–952
- 32 Thorpe, P. E., Wallace, P. M.,

Knowles, P. P. et al. (1987) Cancer Res. 47, 5924–5931

- 33 Julian, R., Duncan, S., Weston, P. D. and Wrigglesworth, R. (1983) Anal. Biochem. 132, 68–73
- 34 Kitagawa, T., Fujiwara, K., Tomonoh, S., Takahashi, K., and Koida, M. (1983) J. Biochem. 94, 1165–1172
- 35 Blatter, W. A., Kuenzi, B. S., Lambert, J. M. and Senter, P. D. (1985) *Biochemistry* 24, 1517–1524
- 36 Fujiwara, K., Saita, T. and Kitagawa, T. (1988) J. Immunol. Methods 110, 47–53
- 37 Vitetta, E., Fulton, R. J., May, R. D., Till, M. and Uhr, J. W. (1987) Science 238, 1098–1104
- 38 Harkonen, S., Stoudemire, S., Jr, Mischak, R. *et al.* (1987) *Cancer Res.* 47, 1377–1382
- 39 Loberboum-Galski, H., FitzGerald, D., Chaudhary, V., Adhya, S. and Pastan, I. (1988) Proc. Natl Acad. Sci. 85, 1922–1926
- 41 Brown, B. A., Davis, G. L., Saltzgaber-Muller, J. et al. (1987) Cancer Res. 47, 3577–3583

Lipases in the preparation of β -blockers

Marcel Kloosterman, Vincent H. M. Elferink, Jack van Iersel, Jan-Hendrik Roskam, Emmo M. Meijer, Lumbertus A. Hulshof and Roger A. Sheldon

β-Adrenergic blocking agents are pharmaceutical products used for the treatment of hypertension and angina pectoris. These β-blockers can be prepared in optically active form by conventional crystallization procedures, by asymmetric chiral synthesis and by using stereoselective enzymes.

Lipases (triacylglycerol acylhydrolase EC 3.1.1.3) occur widely in nature. They belong to the class of serine hydrolases, and therefore do not require cofactors. Their biological function is to catalyse the

Marcel Kloosterman and Emmo Meijer are at DSM Research, Bio-organic chemistry section, PO Box 18, 6160 MD Geleen, Netherlands. Vincent Elferink, Jack van Iersel, Jan-Hendrik Roskam, Lumbertus Hulshof and Roger Sheldon are at Andeno BV, Process Research Laboratory, PO Box 81, 5900 AB Venlo, Netherlands. hydrolysis of triacylglycerols to yield free fatty acids, di- and monoacylglycerols and glycerol. The reaction is reversible: lipases can also catalyse the formation of acylglycerols from free fatty acids and glycerol¹.


Lipases are active at oil-water interfaces of a heterogeneous reaction system, and are thus differentiated from esterases which act on water-soluble substrates in a homogeneous milieu. The preference of lipases for substrates at interfaces seems to be conferred by the presence of interfacial binding sites on the enzyme and not by unique properties of the catalytic site. Since lipases function at an oil-water interface their characterization is rather complicated – one of the reasons why lipases have been studied less extensively than other industrial enzymes such as amylases and proteases.

Applications of lipases

During the last decades, lipolytic enzymes have been used in the dairy and food industry (cheese ripening, production of flavors and cocoa butter substitutes), in detergents, for tanning, sewage treatment and cosmetics $^{2-4}$. For drugs (and agrochemicals) there is an increasing trend towards the use of optically pure stereoisomers, which are more target-specific and show fewer sideeffects than racemic mixtures of Consequently, approval isomers. procedures from the FDA and equivalent regulatory bodies are likely to tighten in the near future. There are therefore important stimuli for companies to market optically pure isomers. This leads to an increasing demand for efficient processes for the industrial-scale synthesis of optically active compounds, which in turn

251





stimulates increased research and development on the production of specialty chemicals via, for instance, lipases or esterases⁵. Development, in some cases, is well advanced: at Chemie-Linz in Austria, a process for the resolution of racemic α -halopropionic acids by lipases^{6–8} is operating on pilot-plant scale; and at Andeno–DSM⁹ the resolution of racemic alkanoic acid oxyranyl methyl esters (glycidyl esters) is performed on a commercial scale.

In this paper we describe the potential application of lipases in the chemoenzymatic synthesis of chiral intermediates for optically active β -adrenergic blocking agents (β -blockers) and compare it with competing technologies.

β-Blockers

 β -Blockers are effective in humans for the treatment of hypertension and angina pectoris. In the pharmaceutical industry some fifty different compounds having β -blocking activity have been brought to some stage of commercial development. About two dozen of these are approved for use and accounted worldwide for \$2.2 billion in revenues in 1985 (Ref. 10).

The aryloxypropanolamine struc-

ture containing one chiral center (Fig. 1) is characteristic of almost all of the FDA-approved β -blockers. In general, β -blocking activity resides in the (S)-enantiomer. For instance, (S)propranolol (Ar, 1-naphthyl; R, isopropyl) is 100 times more active than the (R)-isomer. However, with the exceptions of (S)-timolol (Merck, Sharp & Dohme), (S)-penbutolol (S)-levobunolol (Hoechst) and (Warner-Lambert) (Fig. 2)^{11–13}, all of the FDA-approved β -blockers are marketed as racemates.

For some compounds benefits have been claimed for the (*R*)-enantiomer (e.g. anti-glaucoma activity). Of the ophthalmic β -blockers, both enantiomers are reported to be equally effective in the treatment of glaucoma. Nevertheless, in this case, reduction of the unwanted side-effect (cardiovascular β -blocking) can only be accomplished by removing the (*S*)isomer.

$\begin{array}{l} Preparation \ of \ optically \ active \\ \beta \text{-blockers} \end{array}$

Until the early 1980s, only a few methods, all non-enzymatic, had been described for the preparation of optically active β -blockers. They could be prepared from D-mannitol via (*R*)-2,3-*O*-8-isopropylidene glyceraldehyde^{14,15}, from racemic β blockers by optical resolution^{16,17}, or from racemic 3-*tert*-butylamino-1,2propanediol by optical resolution^{18,19} (Fig. 3). Subsequently, the list of publications and patents concerning enzyme-catalysed processes to chiral intermediates of β blockers has been growing.

Iriuchijima and colleagues at Sagami hydrolysed (±)-1,2-diacetoxy-3-chloropropane enantioselectively with lipoprotein lipase to produce the (S)-enantiomer in 90% enantiomeric excess²⁰ (Fig. 4a). Under alkaline conditions, the (S)enantiomer could be converted with various phenols into the corresponding (S)-3-aryloxy-1,2-propanediols from which several β -blockers [e.g. (S)-propranolol] were synthesized chemically.

Iriuchijima's group also investigated the asymmetric hydrolysis of (\pm) 1-acetoxy-2,3-dichloropropane (Fig. 4b), which is easily prepared from 1-chloro-2-propene (Ref. 21). The recovered ester, (S)-1-acetoxy-2,3-dichloropropane was converted, under basic conditions, into (R)epichlorohydrin, which was converted in situ into (S)-2,3-dichloropropylphenylcarbamate (a compound herbicidal with activity) (S)propranolol and (S)-pindolol.

Optically active epichlorohydrin is a potentially attractive intermediate for a number of industrially relevant chiral chemicals (e.g. β -blockers, L-carnitine, insect pheromones) and the preparation of its separate isomers has been the subject of much research lately. For instance, chiral epichlorohydrin has also been prepared by:

• stereoselective hydrolysis of 2-acyloxy-3-chloropropyl-*p*-toluene-sulphonate by lipase from *Pseudo-monas aeruginosa*²²;


• esterification of 2,3-dichloro-1propanol by lipase from *Candida cylindracea* and tributyrin²³;


• removal of (R)-(+)-2,3-dichloro-1propanol from a racemic mixture by a strain of *Pseudomonas* to yield the (S)-isomer²⁴;

• stereospecific epoxidation of 3chloro-1-propene by a *Mycobacterium* sp.²⁵;

• chemical means (see for example Refs 26 and 27).

Other chiral intermediates of β -blockers have also been produced enzymatically. Ohno and colleagues from Sumitomo used lipase from a *Pseudomonas* species to catalyse asymmetric hydrolysis of (R,S)-1-acetoxy-2-aryloxypropionitrile²⁸ (Fig. 4c). (S)-1-acetoxy-2- α -naphthyloxypropionitrile, obtained by lipolytic resolution, was converted in two steps into (S)-propranolol. The same approach was





Synthesis of (S)-timolol via optical resolution of racemic 3-t-butylamino-1,2-propanediol.

followed by Ohta *et al.*²⁹ who used growing cells of a *Bacillus* strain.

Another route has been developed at Kanegafuchi. Watanabe *et al.*³⁰ synthesized 2-oxazolidinone esters, from glycidol or allylalcohol. The racemic mixtures were subsequently selectively hydrolysed by lipoprotein lipase. Thus, (R,S)-5-acyloxymethyl-3-alkyl-2-oxazolidinones were converted into the corresponding (R)-5-hydroxymethyl-3-alkyl-2oxazolidinones together with the (S)enantiomer of the original 5-acyloxymethyl derivative (Fig. 4d). Treatment of this (S)-derivative with sodium hydroxide yielded the desired (S)-oxazolidinone; the unwanted (R)-by-product could be inverted, giving (S)-hydroxymethyl-3-alkyl-2-oxazolidinone in high overall yield³¹.


Recently an elegant method for lipase-mediated enantioselective hydrolysis of esters of epoxy alcohols was reported by Ladner and Whitesides³²: optically active (R)-glycidyl esters were isolated at laboratory scale using a commercially available lipase preparation from porcine pancreas.

253

At Andeno–DSM the lipase-catalysed resolution of racemic glycidyl butyrate (R in Fig. 4e, C_3H_7) has been improved considerably and is now being exploited on a commercial scale to give (R)-glycidyl butyrate and (R)-glycidol (Fig. 4e) with high enantiomeric excesses. From these chiral products both (R)- and (S)glycidyl tosylate of high enantiomeric purity are prepared.

The high selectivity for O-nucleophilic attack at C-1, makes these tosylates highly attractive intermediates for a number of industrially important chemicals^{33,34} (Fig. 5). In addition, these chiral glycidyl tosylates exhibit an excellent thermal stability, both chemical and optical. Both (R)- and (S)-glycidyl tosylate are being marketed*.

*For industrial purposes, samples may be obtained from: Mr P. Müris, Adeno BV, New Products Development Department, PO Box 81, 5900 AB Venlo, Netherlands.



Competing technologies


Alternative methods for the preparation of chiral intermediates for β-blockers have been reported. For instance, microbial epoxidation of aryl allyl ethers yielding (+)-aryl glycidyl ethers has been reported by scientists from Ibis^{35,36}. So far, the reaction has only been performed at low substrate concentrations and the microorganisms appear not to have a broad substrate specificity. In a more recent patent application from Ibis³⁷ it is disclosed that (R)-1,3-dioxolane-4-methanol [(R)-solketal] can be prepared by treating racemic solketal with microbial cells that stereoselectively metabolize the (S)-isomer. Nevertheless, the large number of chemical steps needed to convert (R)solketal into β -blockers seems to prohibit its use in this way.

An elegant chemical approach to the production of chiral glycidols by asymmetric epoxidation of allyl alcohol was developed by Sharpless and co-workers³⁸. In the original paper, poor yields were obtained because of low extraction yields but improvements have been reported³⁴.

When compared with these technologies or with the production of chiral epichlorohydrin²²⁻²⁷ the production of chiral epoxides by a lipase-catalysed resolution of glycidyl esters is very attractive. It is simple, easy to scale up and the reactions can be performed at very high substrate concentrations. In general, for a lipase-catalysed hydrolytic reaction, separation of the emulsified layers can be a serious problem on an industrial scale. Thus selection of a suitable solvent for extraction is essential. In optimizing our process for the lipase-mediated resolution of racemic glycidyl esters we have managed to solve these problems effectively without recourse to immobilizing the lipase or using a membrane reactor.

Future developments

This review has shown that many chiral intermediates to industrially relevant compounds [e.g. (S)- β blockers, (R)- and (S)-epichlorohydrin] are easily produced using lipolytic enzymes. In our opinion, more attention should be directed towards two ends in particular:



(1) screening for novel lipases with industrially relevant properties (e.g. thermostability, stereoselectivity); and (2) regulating the synthesis of exocellular microbial lipase in order to produce the biocatalyst.

Screening

Some general criteria for goalorientated screening programmes have been put forward by Cheetham³⁹: one can consider using such methods as recombinant-DNA techniques, mutagenesis, medium engineering, and isolation of microorganisms from extreme environments^{39,40}.

Laborious random screening programmes can also be successful; such programmes performed by Japanese scientists from Sumitomo, Sagami and Kanegafuchi led to systems for the resolution of racemates^{20,21,28,30,31}. It has been estimated that less than 1% of the world's microorganisms have been properly examined, so it seems that much scope remains in this area. Lipase synthesis

In general, the activity and amount of lipase produced by microorganisms is strongly dependent on environmental factors such as medium composition and culture conditions. Moreover, culture conditions may also influence the ratio of extra- to intra-cellular lipase production and their specific properties. With respect to medium composition, lipase production is often stimulated by lipids such as lard, olive oil, butter and fatty acids. Effects of polysaccharides, inorganic substances and nitrogen and carbon sources have also been reported.

For fungi, the use of submerged cultures may enhance lipase production in some species, whereas semi-solid cultivation is favorable to others (e.g. *Aspergillus* sp.⁴¹). For instance, *Rhizopus delamar* in semi-solid cultures mainly produced amylase and protease activity, whereas in submerged cultures there was a substantial production of

255

multiform (A, B and C) lipases without the production of proteases⁴². Whether the organism produced B or C lipases could be controlled using selected nitrogen sources and phospholipids⁴². Largescale production of naturally occurring lipases in genetically engineered organisms is also becoming a reality.

Solvent studies

Investigations on model systems for lipase-catalysed reactions should be emphasized in order to obtain a better understanding of the factors that influence the stereo- and regioselectivity of these reactions. Initial results indicate that addition of organic co-solvents markedly influences the regio- and stereoselectivity, stability and activity of some lipases. For instance, a 24-fold increase in enzyme activity was noted when acetone was replaced by more apolar co-solvents (e.g. hexane, di-n-butylether) during the regioselective hydrolysis of a per-Oacetylated carbohydrate by lipase from Candida cylindracea43. Solvents such as carbon tetrachloride⁶⁻⁸ and isooctane⁴⁴ also affected the stereoselectivity, enzyme stability and activity of lipase from *Candida* cylindracea. Lipases can retain their esterification and transesterification activity in nearly anhydrous organic solvents, even at higher temperatures⁴⁵. By covalent attachment to an amphipathic polyethylene glycol polymer, lipases can even be made soluble in organic solvents with (partial) retention of activity⁴⁶.

Protein engineering

Properties of lipases that are potential targets of modification in the future include, for example, stereoselectivity, substrate specificity and affinity, pH and temperature optima, and resistance to inactivation by non-aqueous solvents, heat, high salt concentrations, proteolysis or oxidizing substances. Current knowledge of structure-function relationships of lipases is limited: although more than 300 protein structures have been determined, only one of these is of a lipase (from Geotrichum candidum, determined at 2.5 Å resolution)⁴⁷. Thus it will take considerable time to accumulate

sufficient knowledge on structure– function relationships in lipases to be able to design a lipolytic enzyme with more desirable properties.

Effective future work on the improvement of lipase-based systems for producing pharmaceuticals will demand a coordinated multidisciplinary approach incorporating genetics, recombinant DNA technology, microbial physiology, biochemical engineering, enzymology, protein chemistry and crystallography.

References

- 1 Borgström, B. and Brockman, H. L., eds (1984) *Lipases*, Elsevier
- 2 Dziezak, J. B. (1986) Food Technol. 114–120
- 3 Stead, D. (1986) *J. Dairy Res.* 53, 481– 505
- 4 Seitz, E. W. (1974) J. Am. Oil Chem. Soc. 51, 12–16
- 5 Kamphuis, J., Kloosterman, M., Schoemaker, H. E., Boesten, W. H. J. and Meijer, E. M. (1987) in *Proceedings of the 4th European Congress of Biotechnology* (Vol. 4) (Neijssel, O. M., van der Meer, R. R. and Luyben, K. C. A. M., eds), pp. 331– 348, Elsevier
- 6 Kirchner, G., Scollar, M. P. and Klibanov, A. M. (1985) J. Am. Chem. Soc. 107, 7072-7076
- 7 Klibanov, A. M. (1986) US Patent No. 4601 987
- 8 Dahod, S. K. and Siuta-Mangano, P. (1987) *Biotechnol. Bioeng.* 30, 995– 999
- 9 Sheldon, R. A. (1987) Biotechnol. Ned. 1, 18–19
- 10 Pharmaceutical Products Worldwide (1987) Flemings Research, London
- 11 Wasson, B. K., Gibson, W. K., Stuart, R. S., Williams, H. W. R. and Yates, C. H. (1972) *J. Med. Chem.* 15, 651– 655
- 12 Härtfelder, G., Lessenich, H., and Schmitt, K. (1972) Arzneim-Forsch./ Drug Res. 22, 930–932
- Schwender, C. F., Farber, S., Blaum, C. and Shavel, J. (1970) J. Med. Chem. 13, 684–688
- 14 Tsuda, Y., Yoshimoto, K. and Nishikawa, T. (1981) *Chem. Pharm. Bull.* 29, 3593–3595
- 15 Jurczak, J., Pikul, S. and Bauer, T. (1986) Tetrahedron 42, 447–488
- 16 Howe, R. and Shanks, R. G. (1966) Nature 210, 1336–1338
- 17 Waite, R. (1978) Nouv. Presse Med. 7, 2707–2709
- 18 Rheinhold, D. F. (1976) US Patent No. 4 097 490

- 19 Weinstock, L. M., Mulvey, D. M. and Tull, R. (1976) J. Org. Chem. 41, 3121– 3124
- 20 Iriuchijima, S. and Kojima, N. (1982) Agric. Biol. Chem. 46, 1153–1158
- 21 Iriuchijima, S., Keiyu, A. and Kojima, N. (1982) Agric. Biol. Chem. 46, 1593– 1597
- 22 Hamaguchi, S., Ohashi, T. and Watanabe, K. (1986) Agric. Biol. Chem. 50, 375–380
- 23 Cambou, B. and Klibanov, A. M. (1984) J. Am. Chem. Soc. 106, 2687– 2692
- 24 Kasai, N. (1986) European Patent No. 0207636
- 25 Habets-Crützen, A. Q. H., Carlier, S. J. N., de Bont, J. A. M. et al. (1985) Enzyme Microb. Technol. 7, 17–21
- 26 Baldwin, J. J., Raab, A. W., Mensler, K., Arison, B. H. and McClure, D. E. (1978) J. Org. Chem. 43, 4876–4878
- 27 Ellis, M. K., Golding, B. T. and Watson, W. P. (1984) J. Chem. Soc. Chem. Commun. 1600–1601
- 28 Matsuo, N. and Ohno, N. (1985) Tetrahedron Lett. 26, 5533-5534
- 29 Ohta, H., Miyamae, Y. and Tsuchihashi, G. (1986) Agric. Biol. Chem. 50, 3181–3184
- 30 Kan, K., Miyama, A., Hamaguchi, S., Ohashi, T. and Watanabe, K. (1985) Agric. Biol. Chem. 49, 207–210
- 31 Hamaguchi, S., Asada, M., Hasegawa, J. and Watanabe, K. (1985) Agric. Biol. Chem. 49, 1661–1667
- 32 Ladner, W. E. and Whitesides, G. M. (1984) J. Am. Chem. Soc. 106, 7250– 7251
- 33 McClure, D. E., Arison, B. H. and Baldwin, J. J. (1979) J. Am. Chem. Soc. 101, 3666–3668
- 34 Klunder, J. M., Ko, S. Y. and Sharpless, K. B. (1986) J. Org. Chem. 51, 3710–3712
- 35 Robertson, B. W. *et al.* (1986) European Patent No. 0193.228
- 36 Johnstone, S. L., Phillips, G. T., Robertson, B. W. *et al.* (1987) in *Biocatalysis in Organic Media* (Laane, C., Tramper, J. and Lilly, M., eds), pp. 387–392, Elsevier
- 37 Bertola, M. A., Koger, H. S., Phillips, G. T., Marx, A. F. and Cinneren, V. P. (1987) European Patent No. 0244912
- 38 Katsuki, T. and Sharpless, K. B. (1980) J. Am. Chem. Soc. 102, 5976– 5980
- 39 Cheetham, P. S. J. (1987) Enzyme Microb. Technol. 9, 194–213
- 40 Rowlands, R. T. (1984) Enzyme Microb. Technol. 6, 3–10
- 41 Fukumoto, J., Iwai, M. and Tsujisaka, Y. (1963) J. Gen. Appl. Microbiol. 9, 353–361
- 42 Iwai, M. (1963) Bull. Osaka Munic. Techn. Res. Inst. 39, 63–70



- 43 Kloosterman, M., Mosmuller, E. W. J., Schoemaker, H. E. and Meijer, E. M. (1987) *Tetrahedron Lett.* 28, 2989– 2992
- 44 Sohn, H. S., Chung, S. S. and Rhee,

J. S. (1987) Biotechnol. Lett. 9, 117– 122 45 Klibanov, A. M. (1986) Chem. Tech. 355–359

46 Inada, Y., Yoshimoto, T., Matsushima,

A. and Saito, Y. (1986) Trends Biotechnol. 4, 68–73

47 Hata, Y., Tanaka, N., Kakudo, N., Sugihara, A., Iwai, M. and Tsujisaka, Y. (1981) Acta Crystallogr. A37, C38

Enzymatic synthesis of oligosaccharides

Kurt G. I. Nilsson

As the importance of the oligosaccharide moieties of glycoproteins and glycolipids is being increasingly recognized, efforts to synthesize them are expanding. The number of functional groups of carbohydrate monomers and the variety of configurations that oligomers can adopt is greater than with nucleotides/nucleic acids or amino acids/peptides. By reversing the hydrolytic action of glycosidases and by using highly regiospecific glycosyltransferases, enzymatic oligosaccharide synthesis can be performed.

Why is it necessary to synthesize oligosaccharides? The fundamental answer is that we want to explore and exploit for human ends the biological activity of these polymers following synthetic and biosynthetic work on oligopeptides and oligonucleotides. The complex oligosaccharide chains (glycans) of glycoproteins and glycolipids mediate or modulate a variety of biological processes¹⁻⁹. For example, the glycoconjugate oligosaccharides serve as cell surface receptors (e.g. for influenza and other viruses, bacteria, bacterial toxins, blood-group and tumor-specific antibodies, circulating lymphocytes and for a variety of lectins); they are important for intracellular migration and secretion of glycoproteins and for clearance of glycoproteins from circulation by hepatocytes; they are involved in cell adhesion; they serve as modulators of cell growth; and they change during cellular differentiation. Moreover, there are numerous reports on alterations of glycans after malignant transformation^{2,4,6–11}. Antibodies against cancer-associated carbohydrate anti-

Kurt Nilsson is at Swedish Sugar Co. R&D, Carbohydrates International, PO Box 6, S-232 00 Arlov, Sweden. gens are being used in diagnostic kits (e.g. pancreas, colon cancer)⁶ or in immunotherapy (e.g. melanoma patients)². The importance of the carbohydrate portion of serum glycoproteins for their half-lifes in the circulation and their immunogenicity has been recognized¹² and *in-vitro* glycosylation of recombinant proteins has been attempted¹³.

Knowledge of the various glycoprotein and glycolipid glycan structures has increased dramatically in the last decade because of the development of permethylation¹⁴ and NMR analysis. It is well known that the combination of different amino acids gives a huge variety of peptides and proteins. But the number of possible combinations of a given number of carbohydrates monomers is much higher because there are many possible linkage sites on each and at each site there is the possibility of different anomeric configuration (α - or β -glycosidic linkages). However, the glycan structures of glycoconjugates are not randomly constructed. On the contrary, they may be divided into families in which structures are similar and contain common oligosaccharide sequences (Table 1). The most common carbohydrate chains

in glycoproteins are high-mannoseand complex-type, asparagine-linked (N-glycosidic) or serine/threoninelinked (O-glycosidic) oligosaccharides. Similarly, glycolipids can be divided into five main structural series. Nevertheless, the diversity of the glycoconjugate oligosaccharides evident from Table 1 allows for biological specificity. Indeed, it has been proposed that 'the specificity of many natural polymers is written in terms of sugar residues and not of amino acids or nucleotides' (Ref. 15). The synthesis of such complexes represents a stiff challenge.

Importantly, however, short fragments of glycan structures (Table 1) are sufficient for biological specificity^{1,2,6,11}. These have been used in affinity chromatography, for preparing neoglycoconjugates, for incorporation into liposomes, for immunization, and for characterization of antibodies, glycosidases, glycosyltransferases and lectins. They have also been used in the development of diagnostic kits or targeting of drugs^{7-9,16-19}. For example, a sensitive and specific assay for identifica-

-Glo	ossary
1000	glycon — the non-sugar portion of glycoside
Br	1 – Benzyl (PhCH ₂ -)
+	t – Benzoyl eu5Ac (NeuAc, Sia) – N-Acetyl-
COLUMN ST	uraminic acid
11.10	al – D-Galactopyranose IcNAc – 2-acetamido-2-deoxy-D-
11995	ucopyranose
here in	alNAc – 2-acetamido-2-deoxy-D- lactopyranose
1.025	an – p-mannopyranose
5 860 mg	IC – L-Fucopyranose Abbreviated nomenclature of
	gosaccharides according to IUB- PAC recommendations ⁶⁶ .
	The reconnection and the t

© 1988, Elsevier Science Publishers Ltd (UK) 0167 - 9430/88/\$02.00